



## **Current Status of Integrated Pharmacological and Interventional Treatment of Cancer Pain**

Melisa Hunis MD<sup>1\*</sup>, Adrian Hunis MD<sup>2</sup>

**\*Correspondence to: Melisa Hunis MD**, School of Medicine, Universidad de Buenos Aires (UBA), Argentina.

### **Copyright**

© 2025 **Melisa Hunis**. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 07 May 2025

Published: 19 May 2025

**Abstract**

*Background: Cancer pain is a complex, multifactorial syndrome that significantly impairs quality of life. Despite advances in oncology, pain remains undertreated.*

*Objective: To review the current pharmacological and interventional approaches to cancer pain, including epidemiology, assessment, types, and management strategies.*

*Methods: Literature review of recent guidelines, clinical trials, and meta-analyses.*

*Results: Effective cancer pain management requires a multimodal approach, integrating pharmacological, interventional, psychological, and physiotherapeutic strategies.*

*Conclusion: Despite progress, challenges remain in individualized pain control, opioid stewardship, and access to interventional therapies.*

**Cancer Pain Syndrome**

Cancer pain is defined as pain caused directly by tumor infiltration, cancer-related treatment, or associated complications. It is a multidimensional experience involving physical, emotional, and social components [1]. Cancer pain may be acute or chronic and is often persistent, with episodes of breakthrough pain.

**Epidemiology, Frequency, and Tumor Types Most Associated with Pain**

Cancer pain affects up to 70% of patients with advanced disease [2]. Prevalence varies by cancer type and stage (see Table 1).

Tumor Type	Prevalence of Pain (%)
Head and Neck	67
Lung	57
Breast	54
Colorectal	50
Prostate	45
Pancreatic	80

**Table 1. Prevalence of Pain by Cancer Type**

Adapted from van den Beuken-van Everdingen et al. [2]

Pain is more frequent in advanced and metastatic stages, particularly with bone, pancreatic, and head and neck cancers [3].

#### **D) Semiological Assessment and Pain Measurement**

Accurate pain assessment is crucial. Key elements include:

- Location, intensity, quality, duration, and aggravating/relieving factors
- Impact on function and mood

#### **Pain Measurement Tools:**

- Visual Analog Scale (VAS)
- Numeric Rating Scale (NRS)

- Brief Pain Inventory (BPI)
- McGill Pain Questionnaire

**Table 2. Common Pain Assessment Tools**

Tool	Description	Advantages
VAS	0-10 cm line, patient marks	Simple, quick
NRS	0-10 numeric scale	Easy to administer
BPI	Multidimensional	Assesses impact on function
McGill Questionnaire	Qualitative descriptors	Detailed pain characterization


### Types of Cancer Pain

Cancer pain is heterogeneous:

- Visceral pain: Deep, poorly localized (e.g., liver metastases)
- Somatic (bone) pain: Well-localized, often severe (e.g., bone metastases)
- Neuropathic pain: Burning, shooting, due to nerve infiltration or treatment (e.g., chemotherapy-induced neuropathy)
- Breakthrough pain: Transient exacerbations despite baseline control
- Incident pain: Triggered by movement or procedures
- Refractory pain: Resistant to standard therapies

### Pharmacological Treatment: Analgesic Ladder and Drug Classes

The WHO Analgesic Ladder remains the cornerstone (see Figure 1).



**Figure 1.** The WHO analgesic ladder for treating cancer pain. Adapted from the World Health Organisation.

Figure 1. WHO Analgesic Ladder (Described):

- Step 1: Non-opioids (NSAIDs, acetaminophen)
- Step 2: Weak opioids (codeine, tramadol) ± non-opioids
- Step 3: Strong opioids (morphine, fentanyl) ± adjuvants

Table 3. Pharmacological Agents in Cancer Pain

Class	Examples	Indications	Side Effects
<b>Non-opioids</b>	NSAIDs, acetamin.	Mild pain	GI, renal, hepatic
<b>Weak opioids</b>	Codeine, tramadol	Moderate pain	Nausea, constipation
<b>Strong opioids</b>	Morphine, fentanyl	Severe pain	Sedation, respiratory depr.
<b>Adjuvants</b>	Antidepressants , anticonvulsants	Neuropathic pain	Anticholinergic, sedation
<b>Corticosteroids</b>	Dexamethasone	Bone, neuropathic, edema	Hyperglycemia, myopathy

Morphine is the gold standard for severe cancer pain [4].

Fentanyl patches are preferred in patients with swallowing difficulties or renal impairment [5].

### **Interventional Treatments**

When pharmacological therapy is insufficient or limited by side effects, interventional procedures are considered.

Table 4. Interventional Techniques

Technique	Indication	Strengths	Weaknesses
Nerve blocks (e.g., celiac)	Visceral pain (pancreas)	Targeted, rapid relief	Temporary, procedural risks
Epidural/ intrathecal analgesia	Refractory pain	Potent, reduced systemic SE	Invasive, infection risk
Intrathecal pumps (morphine)	Chronic, refractory pain	Long-term, dose sparing	Cost, device complications
Vertebroplasty/ cementoplasty	Bone metastases	Stabilization, pain relief	Bleeding, cement leakage
Radiofrequency ablation	Bone/soft tissue metastases	Minimally invasive	Limited by lesion location

SE: Side effects

### Psychological Treatment

Psychological interventions are essential in comprehensive pain management. Techniques include:

- Cognitive-behavioral therapy (CBT)
- Relaxation training
- Mindfulness and coping strategies
- Supportive counseling

These approaches reduce pain perception, anxiety, and improve coping [6,7].

### Physiotherapeutic Treatment

Physical therapy aims to maintain function, reduce pain, and improve quality of life:

- Exercise programs

- Manual therapy
- Transcutaneous electrical nerve stimulation (TENS)
- Heat/cold therapy

Physiotherapy is especially beneficial for musculoskeletal and neuropathic pain components [8].

### **Final Summary**

Cancer pain is a prevalent, multifactorial syndrome requiring a multidisciplinary approach. Pharmacological management, based on the WHO ladder, remains foundational, but interventional, psychological, and physiotherapeutic modalities are critical adjuncts. Individualized treatment plans, regular assessment, and patient education optimize outcomes.

### **Future Directions in Cancer Pain Management**

- Personalized medicine: Genetic profiling for opioid response [9]
- Novel analgesics: Peripherally acting opioids, cannabinoids [10]
- Neuromodulation: Spinal cord stimulation, dorsal root ganglion stimulation [11]
- Telemedicine: Remote pain assessment and management [12]
- Integration of palliative care: Early involvement improves pain and quality of life [13]

### **Conclusions**

Optimal cancer pain management requires integration of pharmacological, interventional, psychological, and rehabilitative therapies. Ongoing research into novel agents and techniques, alongside improved access to interventional procedures and palliative care, will further enhance patient outcomes.

### **References**

1. Portenoy RK, Lesage P. Management of cancer pain. *Lancet*. 1999;353(9165):1695-1700.

2. van den Beuken-van Everdingen MH, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. *Ann Oncol.* 2007;18(9):1437-1449.
3. Fallon M, et al. Cancer pain in Europe: a longitudinal study. *Eur J Pain.* 2018;22(3):533-540.
4. Caraceni A, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations. *J Clin Oncol.* 2012;30(5):623-631.
5. Mercadante S, et al. Fentanyl transdermal system for the treatment of cancer pain. *J Pain Symptom Manage.* 2001;21(2):102-109.
6. Syrjala KL, et al. Psychological approaches to cancer pain management. *J Clin Oncol.* 2014;32(16):1703-1711.
7. Bennett MI, et al. Psychological interventions for cancer pain. *Cochrane Database Syst Rev.* 2019;5:CD006275.
8. Oldenmenger WH, et al. Physical therapy for cancer pain: a systematic review. *Pain Physician.* 2018;21(6):541-558.
9. Lotsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. *Pain.* 2006;121(1-2):1-5.
10. Fallon MT, et al. Cannabinoids for cancer pain: efficacy, safety, and pharmacology. *Curr Opin Support Palliat Care.* 2017;11(2):109-115.
11. Deer TR, et al. Neuromodulation for cancer pain and cachexia. *Cancer J.* 2013;19(5):403-410.
12. Watanabe SM, et al. Telemedicine for cancer pain management: a systematic review. *J Telemed Telecare.* 2014;20(6):276-282.
13. Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med.* 2010;363(8):733-742.
14. Bennett MI, et al. Neuropathic pain in cancer: mechanisms and treatment. *Curr Opin Support Palliat Care.* 2012;6(1):15-24.
15. Swarm RA, et al. Adult cancer pain: clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2013;11(8):992-1022.
16. Paice JA, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. *Ann Oncol.*

2018;29(Suppl 4):iv166-iv191.

17. Smith TJ, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. *J Clin Oncol.* 2012;30(8):880-887.

18. Kwon JH. Overcoming barriers in cancer pain management. *J Clin Oncol.* 2014;32(16):1727-1733.

19. Schug SA, Chandrasena C. Pain management of the cancer patient. *Expert Opin Pharmacother.* 2015;16(1):5-15.

20. Vellucci R. Heterogeneity of chronic pain. *Clin Drug Investig.* 2012;32(Suppl 1):3-10..



Medtronic